BRIEF published on 04/11/2025 at 10:35, 1 year 3 months ago Eckert & Ziegler Proposes €0.50 Dividend for FY 2024 Annual General Meeting Dividend Eckert & Ziegler Financial Year 2024 TecDax
PRESS RELEASE published on 04/11/2025 at 10:30, 1 year 3 months ago Eckert & Ziegler Proposes Dividend of € 0.50 for FY 2024 Eckert & Ziegler SE proposes dividend of €0.50 per share for FY 2024. The Annual General Meeting to be held on June 18, 2025 in Berlin Annual General Meeting Shareholders Dividend Eckert & Ziegler SE FY 2024
BRIEF published on 04/10/2025 at 15:05, 1 year 3 months ago Eckert & Ziegler: US Consul Visits Braunschweig Radiopharmaceutical Facility Cancer Treatment Radiopharmaceuticals Lutetium-177 US Consul Visit Expansion Investment
BRIEF published on 04/10/2025 at 15:05, 1 year 3 months ago Eckert & Ziegler : Le consul américain visite l'usine radiopharmaceutique de Braunschweig Traitement Du Cancer Produits Radiopharmaceutiques Lutécium-177 Visite Du Consul Américain Investissement D'expansion
PRESS RELEASE published on 04/10/2025 at 15:00, 1 year 3 months ago Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschweig US Consul General Jason Chue visits Eckert & Ziegler's radiopharmaceutical production site in Braunschweig, witnessing the production of cancer diagnostics and therapy solutions Eckert & Ziegler Cancer Therapy Radiopharmaceuticals Lutetium-177 Transatlantic Cooperation
BRIEF published on 03/27/2025 at 07:50, 1 year 4 months ago Eckert & Ziegler Reports Record Year in 2024 Eckert & Ziegler 2024 Financial Results Medical Segment Isotope Products 2025 Forecast
BRIEF published on 03/27/2025 at 07:50, 1 year 4 months ago Eckert & Ziegler annonce une année record en 2024 Eckert & Ziegler Résultats Financiers 2024 Secteur Médical Produits Isotopiques Prévisions Pour 2025
PRESS RELEASE published on 03/27/2025 at 07:45, 1 year 4 months ago Eckert & Ziegler: Record year 2024 with new all-time highs Eckert & Ziegler SE achieved record sales of €295.8 million in 2024, with significant growth in Medical and Isotope Products segments. Forecasting sales of €320 million and EBIT of €78 million for 2025 Record Sales Eckert & Ziegler SE 2024 Financial Year Medical Segment Isotope Products Segment
BRIEF published on 03/25/2025 at 09:35, 1 year 4 months ago Eckert & Ziegler fournira de l'actinium-225 à Actinium Pharmaceuticals Essais Cliniques Leucémie Myéloïde Aiguë Approvisionnement En Actinium 225 Radiothérapie Ciblée Pénurie Mondiale
BRIEF published on 03/25/2025 at 09:35, 1 year 4 months ago Eckert & Ziegler to Provide Actinium Pharmaceuticals with Actinium-225 Clinical Trials Acute Myeloid Leukemia Actinium-225 Supply Targeted Radiotherapy Global Shortage
Published on 08/10/2026 at 08:00, 2 hours 10 minutes ago Galantas Gold Expands Indiana Drill Program to 12,500 Metres
Published on 08/10/2026 at 08:00, 2 hours 10 minutes ago Results of AGM and Management Update Presentation
Published on 08/07/2026 at 23:15, 2 days 10 hours ago Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 2 days 11 hours ago Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/10/2026 at 09:50, 20 minutes ago Photon Energy N.V. Bond 21/27 (ISIN: DE000A3KWKY4): Signs of a crisis are mounting. What can investors do? Invitation to video conferences (German/English)
Published on 08/10/2026 at 09:00, 1 hour 10 minutes ago Original-Research: Rosenbauer International AG (von NuWays AG): BUY
Published on 08/10/2026 at 09:00, 1 hour 10 minutes ago Original-Research: Bittium Oyj (von NuWays AG): BUY
Published on 08/10/2026 at 09:00, 1 hour 10 minutes ago Synnovis milestone: 2,000 revolutionary blood tests for NHS lung and breast cancer patients
Published on 08/10/2026 at 09:22, 48 minutes ago Number of shares and voting rights - July 2026 (In French only)
Published on 08/10/2026 at 09:22, 48 minutes ago Nombre total d'actions et droits de vote - juillet 2026
Published on 08/10/2026 at 07:00, 3 hours 10 minutes ago BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY
Published on 08/10/2026 at 07:00, 3 hours 10 minutes ago Biophytis annonce l’autorisation de l’étude clinique OBA au Brésil et partage les perspectives de BIO101 dans l’obésité
